270
252
Isodiol Inc. (CSE:ISOL; OTC:ISOLF)
Per Investing.com at time of Writing: BUY
- Isodiol Announces Major International and Expansion Due to Global Demand
- Isodiol International Inc. Announces Letter of Intent to Supply 99.5%+ Pharma-Grade Cannabidiol to Agrima Botanicals
- Isodiol International Inc. Announces Retail Distribution of Pot-O-Coffee
- Isodiol International Inc. Provides Update for Shareholders; Announces Extension of Deadline for Biosynthesis Pharma Group Acquisition
- Isodiol International Inc. Signs Definitive Agreement to Acquire Azure Bottling, LLC.
- Isodiol International Inc. Signs Letter of Intent to Acquire Leading Specialty Vape Retailer KURE Corp
- Isodiol International Inc. Signs Partnership Agreement With Kawacatoose First Nation
- Isodiol International Inc. Announces Conference Sponsorship at Arnold Sports Festival Through ISO-Sport
- Isodiol unit signs distribution deal with Threshold Enterprises
- Isodiol International Inc. Provides Update on Be Tru Wellness, Announces New Distribution Agreement With Threshold Enterprises
- Isodiol snaps up remaining 75% stake in CN Pharma
- Isodiol International Inc. Signs Definitive Agreement to Acquire 100% Of - Canadian National Pharma Group Inc.
- Isodiol International Inc. Announces Partnership With Europe’s Leading MMA Promotion, Cage Warriors; ISO-Sport Product Line to Commence Sales in the European Market
- Isodiol International Inc. Is Proud to Announce the Appointment of Winter Athlete Brand Ambassadors Jazmine Fenlator, Kiley McKinnon, Kimani Griffin, Faye Gulini, and Julia Marino
- Isodiol International Inc. Receives Regulatory (ANVISA) Approval for Isodiolex for the Treatment of Epilepsy and Parkinson’s
An August 2017 Case Study Revisited